Revolution Medicines This Year: Bulls and Bears for RVMD
Investors are buzzing about Revolution Medicines this year as its RAS-focused cancer programs advance. This article l...
Check which passive funds beat the market in 2024 retirement planning and what factors contributed to their outperformance.
28,482 articlesInvestors are buzzing about Revolution Medicines this year as its RAS-focused cancer programs advance. This article l...
As AI features roll out and iPhone upgrades loom, investors face a nuanced picture: potential stock downside from wea...
A leading cybersecurity stock surged about 62% in 2026, propelled by artificial intelligence (ai) innovations. This a...
Palantir chief executive officer Alex Karp charges that frontier AI models are siphoning value from enterprises. The ...
A real estate rally this year is being led by data-center REITs powering AI, pushing the sector to outsized gains eve...
Nebius soars 16% after NVIDIA discloses a 9.3% stake, prompting a rally in AI cloud peers like CoreWeave and Oracle a...
What could Nu Holdings look like a decade from now? This article breaks down growth catalysts, potential paths, and p...
Executives say a non-technical edge—taste and judgment—could help workers survive the AI-driven jobs shakeup. Here's ...
The Doppler token creation platform is extending its reach to Solana, building on its role powering most Base token l...
CoreWeave sits at the center of the AI compute boom, offering scalable GPU capacity. This article breaks down the bul...
When AI dominates headlines, investors often fear every software stock will crumble. This piece digs into whether fig...
DRAM prices in Korea jumped nearly 500% year over year as Micron, Samsung, and SK Hynix tighten control, turning memo...